Retrospective analysis on efficacy of convalescent plasma in acute respiratory distress syndrome due to COVID-19

• Autor(a) principal: Eren,Esma
• Data de Publicação: 2022
• Outros Autores: Ulu-Kılıç,Ayşegül, Korkmaz,Serdal, Yıldız,Merve, Yüksel,Recep Civan, Kılınç-Toker,Ayşin, Arman-Fırat,Emine, Bestepe-Dursun,Zehra, Çelik,Ilhami
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: São Paulo medical journal (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000100012
• topic: COVID-19; Respiratory distress syndrome; COVID-19 serotherapy [supplementary concept]; Coronavirus disease 2019; Convalescent plasma; Acute respiratory distress syndrome.

ABSTRACT BACKGROUND: Coronavirus disease 2019 (COVID-19) is an ongoing global health threat. However, currently, no standard therapy has been approved for the disease. OBJECTIVES: To evaluate the clinical effectiveness of convalescent plasma (CP) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19. DESIGN AND SETTING: Retrospective study conducted at Kayseri City Education and Research Hospital, Kayseri, Turkey. METHODS: The case group consisted of adult patients (> 18 years) with ARDS due to COVID-19 who received CP in combination with antiviral and supportive treatment. These patients were compared with others who only received antiviral and supportive treatment. RESULTS: During the study period, a total of 30 patients with ARDS due to COVID-19 were included. Eleven patients (36%) received CP in combination with antiviral and supportive treatment, whereas nineteen patients (64%) in the control group only received antiviral and supportive treatment. On admission, the median age, demographic and clinical data and initial laboratory test results were similar between the groups (P > 0.05). On the 14th day of treatment, the laboratory values remained similar between the groups (P > 0.05). The mortality rates were not significantly different between the groups. CONCLUSION: CP treatment did not affect mortality or lead to clinical improvement for COVID-19 patients with ARDS.